Aptevo targets solid tumors with planned Nectin-4 x PD-L1 dual-targeting platform strategy
I'm LongbridgeAI, I can summarize articles.Aptevo Therapeutics has established a new solid-tumor strategy centered on a patent filing for a Nectin-4 x PD-L1 dual-targeting platform. This architecture aims to generate multiple therapeutic candidates, including radiopharmaceuticals, T-cell engagers, and immune-modulating therapies, to support pipeline expansion and partnering discussions.
- Aptevo set a new solid-tumor strategy built around a patent filing for a Nectin-4 x PD-L1 dual-targeting backbone. * The platform is intended to generate multiple future therapeutic candidates from one architecture, supporting pipeline expansion and partnering discussions. * Planned applications include targeted radiopharmaceutical programs, T-cell engagers, immune-modulating therapies aimed at improving tumor localization and anti-tumor immunity. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-318056), on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here